Dr Thanigasalam was born in London (England), and was awarded his MB BS from the University of London before moving to Sydney. He completed his specialist urological training in Sydney, and also gained a Masters of Surgery in Urology at the University of Sydney & The Garvan Institute. At the completion of his Masters of Surgery, he was awarded the John Lowenthal medal for his work on quality of life outcomes following treatment for localised prostate cancer.
After gaining his FRACS (Urology), Dr Thanigasalam trained for a further two years in Paris to sub-specialise in Robotic & minimally invasive surgery (for urological malignancies and female prolapse) and laser surgery (for enlarged prostate & kidney stones). He was trained by some of Europe’s finest robotic urological surgeons. Dr Thanigasalam is currently one of a handful of urological surgeons in Australia & New Zealand to hold a prestigious French robotic & laser prostate fellowship.
Dr Thanigasalam has numerous peer-reviewed publications in the urological literature and is regularly invited to present his research on robotic and minimally invasive surgery at international urology conferences. He also enjoys teaching trainee surgeons in robotic surgery and is a Da Vinci accredited robotic proctor.
Dr Thanigasalam is privileged to teach Urology registrars and medical students affiliated with the Urological Society of Australia & NZ and the University of Sydney, respectively. He is a member of the Urological Society of Australia & NZ (USANZ), the Royal Australasian College of Surgeons (RACS) and the European Association of Urology (EAU). He is one of the Urology Clinical Research Lead investigators at the Institute of Academic Surgery. He is actively involved in research projects looking at the use of minimally invasive and robotic surgery for the treatment of urological malignancies and female genital prolapse. The aim of Dr Thanigasalam’s practice is to provide his patients with compassionate care and the most up-to-date treatment options so that their health is restored in the shortest possible time and with the best oncological and functional outcomes.